Jinyu Bio-technology Balance Sheet Health
Financial Health criteria checks 6/6
Jinyu Bio-technology has a total shareholder equity of CN¥5.5B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥6.9B and CN¥1.4B respectively. Jinyu Bio-technology's EBIT is CN¥107.6M making its interest coverage ratio -2. It has cash and short-term investments of CN¥1.3B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -2x |
| Cash | CN¥1.31b |
| Equity | CN¥5.55b |
| Total liabilities | CN¥1.35b |
| Total assets | CN¥6.90b |
Recent financial health updates
No updates
Recent updates
The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically
Sep 04
Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Sep 02Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge
Jun 16Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year
Apr 30There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price
Mar 21Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?
Feb 28Financial Position Analysis
Short Term Liabilities: 600201's short term assets (CN¥2.4B) exceed its short term liabilities (CN¥693.7M).
Long Term Liabilities: 600201's short term assets (CN¥2.4B) exceed its long term liabilities (CN¥660.3M).
Debt to Equity History and Analysis
Debt Level: 600201 is debt free.
Reducing Debt: 600201 has no debt compared to 5 years ago when its debt to equity ratio was 1.1%.
Debt Coverage: 600201 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 600201 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 04:01 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jinyu Bio-technology Co., Ltd. is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jia Chen | Changjiang Securities Co. LTD. |
| Fu Yang | Chasing Securities |